First solution to combine Computer-Aided Detection and Computed Radiography
for Mammography is Now Available
NASHUA, N.H., April 4, 2008 /PRNewswire-FirstCall/ -. iCAD(R), Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions, today announced that iCAD's SecondLook(R) Digital Computer-Aided Detection system for mammography received approval from the U.S. Food and Drug Administration for sale with Fujifilm Computed Radiography for Mammography (FCRm) systems. SecondLook Digital for FCRm is the first CAD product approved and available in the U.S. for use with computer radiography (CR).
"The addition of CAD functionality to CR digital mammography takes screening and diagnostic capabilities to an unprecedented level," said Rachel Brem, M.D., Director of Breast Imaging and Interventional Care at the George Washington University Hospital. "CAD improves upon existing mammography systems by providing an ability to find overlooked cancers, helping the radiologist find cancer earlier and ultimately improve the level of care for every patient."
"iCAD's SecondLook Digital system coupled with the Fuji CR Mammography system will improve our ability to detect potentially malignant calcifications and masses and we expect that it will increase our overall standard of care," said Jeffrey Mendel, M.D., Chairman of Radiology at Caritas St. Elizabeth's Medical Center in Boston, Massachusetts. "Additionally, seamless integration of iCAD's product with our PACS system will improve the efficiency of our reading and our overall digital workflow."
Since Fujifilm received FDA approval for FCRm in July 2006, the company has enjoyed record sales in the U.S. market, enabling the conversion to digital of nearly 500 mammography exam rooms. FCRm is the world's most widely used digital mammography technology with shipment of more than 4,400 systems worldwide.
"Fujifilm and iCAD are prepared for a fast market roll-out. We have seen steadily increasing interest in CAD from existing and new Fujifilm customers. Our support teams are cross-trained and will work closely to provide complete and timely installations for customers that choose the powerful combination of iCAD and Fuji FCRm solutions," said Ken Ferry, president and CEO of iCAD.
"Fujifilm is extremely pleased to work with iCAD to bring this combination of advanced digital technology to market," said Andy Vandergrift, Fujifilm's National Marketing Manager, Women's Healthcare Imaging. "Fujifilm has already realized great success with FCRm and has the most complete acquisition-to-archive solution for digital mammography, including our Synapse(R) PACS. This combined offering with iCAD -- that is fully compatible with Synapse -- will enhance our product offering even further, broadening its appeal to even more facilities."
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems for the high, mid and low volume mammography markets. iCAD is entrusted with the task of early cancer detection by more than 2000 women's healthcare centers worldwide. For more information, call +1 877 iCADnow or visit http://www.icadmed.com.
About FUJIFILM Medical Systems USA, Inc.
As one of the FUJIFILM Corporation family of companies with 70 years of imaging experience and almost $25 billion in sales, FUJIFILM Medical Systems USA Inc. is a leading provider of diagnostic imaging products and network systems to meet the needs of healthcare facilities today and well into the future. Fujifilm's family of Imaging Systems products and technologies -- including digital x-ray, women's healthcare imaging, dry imagers, and conventional x-ray film and equipment -- are tailored to suit many different applications for a variety of imaging environments. Fuji Computed Radiography for Mammography (FCRm) has long been the world's most widely used Full Field Digital Mammography (FFDM) solution, and is already making a notable impact on the FFDM market in the United States since receiving FDA approval. FUJIFILM Medical Systems USA is headquartered in Stamford, CT. More information is available at http://www.fujimed.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements involve a
number of known and unknown risks, uncertainties and other factors which
may cause the actual results, performance or achievements of the Company to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Such
factors include, but are not limited to, the risks of uncertainty of patent
protection, the impact of supply and manufacturing constraints or
difficulties, product market acceptance, possible technological
obsolescence, increased competition, customer concentration and other risks
detailed in the Company's filings with the Securities and Exchange
Commission. The words "believe", "demonstrate", "intend", "expect",
"estimate", "anticipate", "likely", and similar expressions identify
forward-looking statements. Readers are cautioned not to place undue
reliance on those forward-looking statements, which speak only as of the
date the statement was made. The Company is under no obligation to provide
any updates to any information contained in this release.
For iCAD, contact Darlene Deptula-Hicks at 603-882-5200 x7944, or via email at
email@example.com For Investor Relations, contact Anne Marie Fields of Lippert/Heilshorn &
Associates at 212-838-3777 x6604 or via email at firstname.lastname@example.org
For Public Relations, contact Jill Testagrossa of Schwartz Communications at
781-684-0770 or via e-mail at email@example.com
|SOURCE iCAD, Inc.|
Copyright©2008 PR Newswire.
All rights reserved